Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.
about
Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetesMechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview.A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.Time of effect duration and administration interval for sitagliptin in patients with kidney failure.
P2860
Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Mechanism-based population pha ...... te of dipeptidyl peptidase IV.
@ast
Mechanism-based population pha ...... te of dipeptidyl peptidase IV.
@en
type
label
Mechanism-based population pha ...... te of dipeptidyl peptidase IV.
@ast
Mechanism-based population pha ...... te of dipeptidyl peptidase IV.
@en
prefLabel
Mechanism-based population pha ...... te of dipeptidyl peptidase IV.
@ast
Mechanism-based population pha ...... te of dipeptidyl peptidase IV.
@en
P2093
P2860
P1476
Mechanism-based population pha ...... te of dipeptidyl peptidase IV.
@en
P2093
Cornelia B Landersdorfer
William J Jusko
Yan-Ling He
P2860
P304
P356
10.1111/J.1365-2125.2011.04108.X
P407
P577
2012-03-01T00:00:00Z